CXCL12 and neoplasm: When rats bearing glioblastoma multiforme were treated with a combination of anti-VEGF antibodies and NOX-A12, CXCL12 blockade enhanced the effect of anti-VEGF therapy by inhibiting TAM recruitment and further reducing the tumor microvasculature [317].